As of September 1, 2010, Olivier BOHUON, NATF Fellow, will be joining the Pierre Fabre Group, replacing Jean-Pierre GARNIER as the Group's Chief Executive Officer.
© Pierre FabreAs of September 1, 2010, Olivier BOHUON will be joining the Pierre Fabre Group, replacing Jean-Pierre GARNIER as the Group's Chief Executive Officer. 51 years of age, Olivier BOHUON is currently Executive Vice-President of Abbott Corporation and President of the Pharmaceutical Division. From his Chicago office, Olivier BOHUON directed all the pharmaceutical activities of the Group (turnover 22 billion US dollars); since 2003, he was successively President for European activities and President for Abbott International. He started his career with Roussel UCLAF in Morocco then with their Middle East Area. Olivier BOHUON was Executive Director of Marketing then General Operational Manager for Glaxo France (1991-1995), CEO then Chairman for SmithKline Beecham Laboratories (1995-2001) and General Manager for European Activities for Glaxo SmithKline (2001-2003).Olivier BOHUON holds a Doctor's degree in Pharmeutical Sciences and also is an MBA graduate of HEC (France). He is Fellow of the National Academy for Phamaceutical Sciences of France and also Fellow of NATF; he was distinguished as Chevalier (Knighthood) of the French Legion d'Honneur.Following his earlier international career, during which he assumed top level responsibilities in pharmaceutical activities, Olivier BOHUON expressed the wish to pursue his career in France. In addition to his new position with Pierre Fabre Group, Olivier BOHUON will be Chairman of Pierre Fabre Medicament (medicinal sector).When the appointment was announced, Olivier BOHUON stated that he was: " ... very happy to join the staff of one of the most important independent industrial groups in France - I know them well and have admired their track-record. My intention is to manage the Group in close collaboration with the Founder-Chairman with whom I shall actively prepare the future of the Group - my efforts will be directed to assuring continuity of the group's success ".
The Pierre Fabre Group
"Groupe Pierre Fabre", is the second French independent pharmaceutical industrial laboratory and leader in cosmetics sold in chemistry outlets. The Group employs close on 10 000 personnel, 1 400 of whom work in the Group's &D acrivities. For yr. 2009, Pierre fabre Medicament invested 28% of the turnover to R&D in 4 main directions that are seen as priorities - cancer treatments, central nervous system disorders, dermatology and the continuum cardiovascular/metabolism.